REGENXBIO (RGNX) Q1 2026 earnings snapshot

REGENXBIO (RGNX) has just posted Q1 2026 results with revenue of US$6.4 million and a basic EPS loss of US$1.72, against a trailing twelve month basic EPS loss of US$5.59 on revenue of US$87.8 million. Over recent quarters the company has reported revenue of US$89.0 million in Q1 2025, followed by US$21.4 million in Q4 2024. Basic EPS moved from a profit of US$0.12 in Q1 2025 to a loss of US$1.01 in Q4 2024. These figures are likely to draw investor attention to how prospects for revenue growth compare with currently compressed margins.

See our full analysis for REGENXBIO.

With the headline numbers on the table, the next step is to see how this latest earnings report aligns with the key bullish and bearish narratives investors have been following around REGENXBIO.

Losses widen as net income stays deeply negative

• Net income for Q1 2026 was a loss of US$90.1 million, compared with losses of US$67.1 million in Q4 2025 and US$51.2 million in Q4 2024, while trailing twelve month net income moved to a loss of US$290.0 million from a loss of US$193.9 million a year earlier.
• Bears highlight that losses have grown at about 21.4% per year over the past five years, and the latest figures fit that concern, with:
  • Quarterly losses deepening even as Q1 2026 revenue of US$6.4 million sits well below the US$30.3 million and US$29.7 million levels seen in Q4 and Q3 2025.
  • Trailing twelve month basic EPS moving further into loss territory at US$5.59 compared with US$3.10 a year earlier, which aligns with the view that profitability is not yet in sight.

Skeptics warn that this pattern of larger losses on a smaller revenue base supports their concern about the path to sustainable earnings and potential funding needs. 🐻 REGENXBIO Bear Case

Revenue swings against a 34.5% growth outlook

• Revenue over the last twelve months came in at US$87.8 million, compared with US$170.4 million on a trailing basis at Q4 2025, yet forecasts still point to about 34.5% annual revenue growth from this base.
• Bullish investors focus on that forecast growth rate and the gene therapy pipeline, but the recent revenue pattern gives a mixed backdrop, because:
  • Quarterly revenue has moved from US$89.0 million in Q1 2025 to US$21.4 million in Q4 2024 and US$6.4 million in Q1 2026, which is a very different profile from the smoother growth path bulls often assume.
  • Despite this, the stock trades at a P/S of 3.7x, below peer and industry averages of 8.2x and 10.6x, which bulls may see as leaving room for sentiment to improve if forecasts play out.

Bulls argue that if the forecast revenue growth materializes, the current discount in the P/S ratio could look conservative relative to the late stage pipeline. 🐂 REGENXBIO Bull Case

Cash runway risk beside discounted valuation

• The company is reported to have less than one year of cash runway and remains unprofitable on trailing twelve month metrics, while the stock trades on a P/S of 3.7x, below the 8.2x peer average and 10.6x for the US biotech industry.
• Critics point out that the constrained cash position and ongoing losses could become a bigger issue than any perceived valuation discount, because:
  • Forecasts indicate the business is expected to remain unprofitable over the next three years, so funding operations through that period may require fresh capital if internal cash generation does not improve.
  • At the same time, the current share price of US$6.25 sits well below the 26.64 analyst price target referred to in the narratives, which suggests the market is already weighing financing risk against the growth story.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for REGENXBIO on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seen enough mixed signals to feel torn about the stock's direction? Check the underlying data, weigh both sides, and decide where you stand with 1 key reward and 3 important warning signs

Explore Alternatives

REGENXBIO is facing deepening losses on a shrinking revenue base and a short cash runway, which raises questions about financial resilience through future funding needs.

If that level of pressure on the balance sheet worries you, shift some research time toward companies with stronger cushions by checking the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.